Segall Bryant & Hamill LLC Increases Stake in McKesson Co. (NYSE:MCK)

Segall Bryant & Hamill LLC grew its stake in McKesson Co. (NYSE:MCK - Free Report) by 25.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 81,223 shares of the company's stock after buying an additional 16,502 shares during the quarter. McKesson makes up 0.6% of Segall Bryant & Hamill LLC's portfolio, making the stock its 29th biggest holding. Segall Bryant & Hamill LLC owned 0.06% of McKesson worth $46,290,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Cerity Partners LLC boosted its position in shares of McKesson by 7.6% in the third quarter. Cerity Partners LLC now owns 44,224 shares of the company's stock worth $21,867,000 after purchasing an additional 3,127 shares during the period. Penserra Capital Management LLC boosted its holdings in McKesson by 21.7% in the 3rd quarter. Penserra Capital Management LLC now owns 1,075 shares of the company's stock worth $530,000 after buying an additional 192 shares during the period. Larson Financial Group LLC increased its stake in McKesson by 4.3% in the 3rd quarter. Larson Financial Group LLC now owns 1,141 shares of the company's stock worth $564,000 after buying an additional 47 shares in the last quarter. Centaurus Financial Inc. raised its holdings in McKesson by 518.4% during the third quarter. Centaurus Financial Inc. now owns 2,152 shares of the company's stock valued at $1,064,000 after acquiring an additional 1,804 shares during the period. Finally, Summit Trail Advisors LLC lifted its position in shares of McKesson by 11.9% in the third quarter. Summit Trail Advisors LLC now owns 1,401 shares of the company's stock valued at $693,000 after acquiring an additional 149 shares in the last quarter. Institutional investors own 85.07% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on MCK shares. Wells Fargo & Company increased their target price on McKesson from $641.00 to $691.00 and gave the stock an "equal weight" rating in a research report on Friday, March 14th. Mizuho began coverage on shares of McKesson in a report on Wednesday, December 4th. They set a "neutral" rating and a $630.00 price objective for the company. Bank of America lowered their target price on shares of McKesson from $680.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, January 6th. Morgan Stanley raised their target price on shares of McKesson from $612.00 to $642.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. Finally, StockNews.com cut shares of McKesson from a "strong-buy" rating to a "buy" rating in a research note on Friday, February 14th. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $649.36.

Insiders Place Their Bets

In related news, EVP Leann B. Smith sold 188 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the sale, the executive vice president now directly owns 1,051 shares of the company's stock, valued at approximately $640,679.09. This trade represents a 15.17 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $600.66, for a total value of $5,382,514.26. Following the completion of the transaction, the chief executive officer now directly owns 69,625 shares in the company, valued at $41,820,952.50. This trade represents a 11.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,689 shares of company stock valued at $11,187,351 over the last 90 days. Insiders own 0.11% of the company's stock.

McKesson Price Performance

Shares of NYSE:MCK traded up $2.58 during trading on Friday, hitting $668.25. The company had a trading volume of 566,680 shares, compared to its average volume of 837,100. The stock has a market cap of $83.75 billion, a price-to-earnings ratio of 30.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The company has a fifty day simple moving average of $623.58 and a two-hundred day simple moving average of $579.34. McKesson Co. has a one year low of $464.42 and a one year high of $672.00.

McKesson (NYSE:MCK - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. On average, equities research analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 0.42%. The ex-dividend date is Monday, March 3rd. McKesson's dividend payout ratio (DPR) is currently 13.00%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.